Obesity coverage on Peptide News Digest follows the drugs that actually reshape body weight at scale: GLP-1 agonists, GIP/GLP-1 dual and triple agonists, amylin combinations, and the next layer behind them.
Headline reads from 2025 and 2026: SURMOUNT-5 (tirzepatide vs semaglutide head-to-head), ACHIEVE-3 (orforglipron in obesity), REDEFINE-1 (CagriSema), the SELECT cardiovascular outcomes trial in non-diabetic adults with obesity, and a steady stream of real-world evidence showing the gap between trial weight loss and 12-month routine-care outcomes. Adherence and discontinuation are now the most cited weak points in the category.
The other half of obesity coverage is access — payer policy, Medicare and CMS rulings, the compounding economy, telehealth distribution, and the OMA conference circuit. Browse the latest below.
Ahead of the European Congress on Obesity in Istanbul (May 12–15), a 21-expert global panel of obesity and cancer specialists will present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists like semaglutide and tirzepatide for prevention of obesity-related cancers. The proposal builds on the SELECT trial's established cardiovascular benefit, real-world dementia-incidence reductions, and the broader case that GLP-1s influence multiple aging-driven disease categories. The Istanbul meeting is the same venue where Novo Nordisk will present 52 abstracts on Wegovy, the higher-dose 7.2 mg formulation, the Wegovy pill, and CagriSema, including data on women's obesity, perimenopause, and migraine.
On the April 23 Q1 call and follow-up coverage, Roche clarified that its two Phase 3 enicepatide (CT-388) obesity trials — ENITH 1 and ENITH 2 — were both successfully initiated in Q1, with the dual GLP-1/GIP agonist on track to compete in the next-wave Phase 3 obesity readouts. Phase 2 reported 22.5% placebo-adjusted weight loss for enicepatide. Roche also confirmed the petrelintide+enicepatide fixed-dose combination Phase 2 will dose its first patient around mid-2026, pairing the Zealand-derived amylin analog (placebo-like tolerability, 10.7% mean weight loss in ZUPREME-1 at week 42) with Roche's stronger GLP-1/GIP backbone. Additional Phase 2 readouts for oral GLP-1 CT-996 are guided before year-end 2026.
A Nature paper from Liskiewicz, DiMarchi, Tschöp, Müller and colleagues introduces a unimolecular peptide-drug conjugate that combines a GLP-1R/GIPR co-agonist peptide with the pan-PPAR (α/γ/δ) agonist lanifibranor via a pH-sensitive linker. After receptor-mediated internalization, the linker cleaves and lanifibranor escapes to the nucleus to activate PPARs while the peptide moiety drives GLP-1R/GIPR signaling at the membrane. In obese, diabetic mice the conjugate produced greater weight loss and insulin sensitization than equimolar dosing of the unconjugated peptide and lanifibranor, without the typical PPAR-related cardiac and weight-gain safety signals.
Boehringer Ingelheim confirmed completion of the 76-week primary endpoint visit for the last participant in Phase 3 SYNCHRONIZE-1. Topline data expected H1 2026 — making it one of the year's most anticipated obesity readouts. Survodutide is a glucagon/GLP-1 dual agonist co-developed with Zealand Pharma. The comprehensive SYNCHRONIZE program also includes SYNCHRONIZE-CVOT (cardiovascular outcomes, fully enrolled). All key trials are scheduled to read out at scientific meetings throughout 2026, potentially paving the way for regulatory submission as the third major obesity GLP-1-class drug after semaglutide and tirzepatide.
WHO's December 2025 first-ever GLP-1 guideline for obesity treatment in adults — published as a JAMA Special Communication and updated through Q1 2026 — continues to influence national and payer policy. WHO issued conditional recommendations for chronic GLP-1 therapy as part of comprehensive obesity management, while flagging cost, long-term safety, health-system preparedness, and equity implications. The framework directly informs the political economy of the U.S. Medicare Bridge program extension to 2027 and similar coverage debates globally.
MBX Biosciences announced an April 23 press release confirming its May 11 virtual Obesity Day event, at which the company will formally update investors on its Precision Endocrine Peptide (PEP) platform. The portfolio includes MBX 4291 (Phase 1 GLP-1/GIP co-agonist prodrug designed for once-monthly dosing), an amycretin prodrug with Q2 2026 nomination expected, and a GLP-1/GIP/GCGR triple agonist prodrug with Q3 2026 nomination — all targeting once-monthly administration. Richard DiMarchi and Katherine Saunders will headline the event.
An April 22 NPR report citing GoodRx research found that 12 million people each lost insurance coverage for Wegovy and Zepbound between 2025 and 2026, while 88% of those still covered face restrictions like prior authorization or BMI 40+ requirements. About 60% of GLP-1 users now pay out of pocket — often hundreds of dollars monthly — reframing the affordability debate after the BALANCE model's cancellation.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.
The first definitive Phase 3B head-to-head trial of Lilly's tirzepatide versus Novo Nordisk's semaglutide in 750 patients with obesity over 72 weeks showed tirzepatide produced 21.6% mean weight loss vs semaglutide's 15.4%. 36.2% of tirzepatide patients achieved ≥25% weight loss vs 19.4% on semaglutide. Results published April 20 give Lilly a clear comparative data point in the GLP-1 market share battle.
Novo Nordisk and OpenAI announced a partnership to deploy AI across R&D, manufacturing, and corporate functions, with pilot programs launching immediately and full integration targeted by end of 2026. The deal positions Novo to analyze complex datasets, identify new drug candidates, and compress R&D timelines as it fights to claw back market share from Eli Lilly. OpenAI will also provide AI literacy training to Novo's global workforce.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
Stanford scientists used AI to identify BRP, a naturally occurring peptide that acts directly on the hypothalamus to suppress appetite — avoiding the gut-related side effects of current GLP-1 drugs. In animal studies, BRP reduced body weight and fat without nausea, constipation, or muscle loss. Published in Nature, with human trials planned.
A poster at the Obesity Medical Association annual conference (April 10-12, San Diego) showed tirzepatide achieved greater body weight reduction than semaglutide at 12 months in a real-world Truveta EHR analysis of adults with obesity without diabetes, consistent with SURMOUNT-5 clinical trial results.
The American Diabetes Association published new pharmacologic obesity treatment standards in its journal Diabetes, Obesity, and Cardiometabolic Care, calling on clinicians and policymakers to eliminate weight stigma. Over 40% of people with class II obesity report weight-based discrimination that impedes treatment access.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
The Atlantic examines how GLP-1 pills are reshaping obesity treatment. The shift from weekly injections to daily pills addresses a major compliance barrier, though patients must continue therapy indefinitely.
Over 80 pharmaceutical companies are running clinical trials in obesity. Boehringer Ingelheim is advancing survodutide into three global Phase III trials, positioning it as a key next-generation GLP-1 competitor.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.